Non-Hodgkin's lymphoma vaccine - XEME BiopharmaAlternative Names: B-cell lymphoma vaccine - XEME Biopharma; Follicular lymphoma vaccine - XEME Biopharma; Oncoquest-L; Oncoquest-L vaccine
Latest Information Update: 31 Mar 2017
$50 / €47 *
At a glance
- Originator XEME Biopharma
- Class Cancer vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Natural killer cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 31 Mar 2017 XEME Biopharma's Non-Hodgkin's-lymphoma-vaccine is still at phase I development stage in USA (SC) (Xeme Biopharma pipeline, March 2017).
- 08 Jun 2016 Oncothyreon is now called Cascadian Therapeutics
- 02 Mar 2016 XEME Biopharma plans a phase II trial for Follicular lymphoma (First-line therapy, Late-stage disease) in USA (NCT02194751)